These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 7974335

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M, Sawamoto Y, Kamisue M, Shibata Y, Tuzi S, Kuwabara M, Tanaka I, Tanizawa T, Tanaka A, Ueda M, Kakishita E, Yoshioka A.
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [Abstract] [Full Text] [Related]

  • 25. [Transient inhibitors developed in two cases of hemophilia A].
    Fujiwara F, Kanoh G, Ogawa H, Takaya K, Hibi S, Shima M, Yoshioka A, Imashuku S.
    Rinsho Ketsueki; 1997 Dec; 38(12):1263-8. PubMed ID: 9455145
    [Abstract] [Full Text] [Related]

  • 26. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos AM, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M.
    Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
    [Abstract] [Full Text] [Related]

  • 27. Management of haemophilia A with antibodies--the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide.
    Hedner U, Tengborn L.
    Thromb Haemost; 1985 Dec 17; 54(4):776-9. PubMed ID: 3937274
    [Abstract] [Full Text] [Related]

  • 28. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D.
    Thromb Haemost; 1994 May 17; 71(5):544-7. PubMed ID: 8091377
    [Abstract] [Full Text] [Related]

  • 29. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T, GTH PUP Study Group.
    Haematologica; 2003 Jun 17; 88(6):EREP04. PubMed ID: 12826530
    [Abstract] [Full Text] [Related]

  • 30. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
    Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF.
    Thromb Haemost; 1999 Jan 17; 81(1):35-8. PubMed ID: 9974371
    [Abstract] [Full Text] [Related]

  • 31. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J.
    Thromb Haemost; 1993 Feb 01; 69(2):115-8. PubMed ID: 8456422
    [Abstract] [Full Text] [Related]

  • 32. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B.
    Haematologica; 2005 Sep 01; 90(9):1288-90. PubMed ID: 16154861
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.
    Mariani G, Ghirardini A, Bellocco R.
    Thromb Haemost; 1994 Jul 01; 72(1):155-8. PubMed ID: 7974364
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J, Rzymkiewicz L, Lopaciuk S.
    Acta Haematol Pol; 1996 Jul 01; 27(1):27-31. PubMed ID: 8629440
    [Abstract] [Full Text] [Related]

  • 37. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E.
    Thromb Haemost; 1998 Apr 01; 79(4):762-6. PubMed ID: 9569189
    [Abstract] [Full Text] [Related]

  • 38. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R, Quintana Gonzalez S, Martinez Murillo C, Dominguez Garcia V, Rodriguez Moyado H, Collazo Jaloma J.
    Arch Med Res; 1996 Apr 01; 27(1):15-8. PubMed ID: 8867361
    [Abstract] [Full Text] [Related]

  • 39. Rituximab in the treatment of high responding inhibitors in severe haemophilia A.
    Moschovi M, Aronis S, Trimis G, Platokouki H, Salavoura K, Tzortzatou-Stathopoulou F.
    Haemophilia; 2006 Jan 01; 12(1):95-9. PubMed ID: 16409183
    [Abstract] [Full Text] [Related]

  • 40. Low-dose immune tolerance induction in hemophilia A patients with inhibitors.
    Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM.
    Blood; 1995 Aug 01; 86(3):983-8. PubMed ID: 7620189
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.